JP7133551B2 - 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法 - Google Patents

抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法 Download PDF

Info

Publication number
JP7133551B2
JP7133551B2 JP2019526287A JP2019526287A JP7133551B2 JP 7133551 B2 JP7133551 B2 JP 7133551B2 JP 2019526287 A JP2019526287 A JP 2019526287A JP 2019526287 A JP2019526287 A JP 2019526287A JP 7133551 B2 JP7133551 B2 JP 7133551B2
Authority
JP
Japan
Prior art keywords
angptl8
antibody
antibodies
antigen
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019526287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500852A (ja
JP2020500852A5 (OSRAM
Inventor
ヴィクトリア・グサロヴァ
ジェスパー・グロマーダ
アンドリュー・ジェイ・マーフィー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020500852A publication Critical patent/JP2020500852A/ja
Publication of JP2020500852A5 publication Critical patent/JP2020500852A5/ja
Application granted granted Critical
Publication of JP7133551B2 publication Critical patent/JP7133551B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019526287A 2016-11-17 2017-11-16 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法 Active JP7133551B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423639P 2016-11-17 2016-11-17
US62/423,639 2016-11-17
PCT/US2017/062103 WO2018094112A1 (en) 2016-11-17 2017-11-16 Methods of treating obesity with anti-angptl8 antibodies

Publications (3)

Publication Number Publication Date
JP2020500852A JP2020500852A (ja) 2020-01-16
JP2020500852A5 JP2020500852A5 (OSRAM) 2020-12-17
JP7133551B2 true JP7133551B2 (ja) 2022-09-08

Family

ID=60655071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019526287A Active JP7133551B2 (ja) 2016-11-17 2017-11-16 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法

Country Status (13)

Country Link
US (1) US10442856B2 (OSRAM)
EP (1) EP3541839A1 (OSRAM)
JP (1) JP7133551B2 (OSRAM)
KR (1) KR20190078650A (OSRAM)
CN (1) CN110036029A (OSRAM)
AU (1) AU2017363143B2 (OSRAM)
CA (1) CA3044249A1 (OSRAM)
EA (1) EA201991203A1 (OSRAM)
IL (1) IL266564A (OSRAM)
MA (1) MA46842A (OSRAM)
MX (1) MX382035B (OSRAM)
WO (1) WO2018094112A1 (OSRAM)
ZA (1) ZA201902608B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3822287A1 (en) 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
EP3749691A4 (en) 2017-11-10 2021-10-27 NGM Biopharmaceuticals, Inc. ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
PH12022550141A1 (en) 2019-07-19 2023-12-04 Oncoresponse Inc Immunomodulatory antibodies and methods of use thereof
CN110694067A (zh) * 2019-11-06 2020-01-17 首都医科大学附属北京安贞医院 一种抑制血管生成素样蛋白8的物质的应用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN111690058B (zh) * 2020-03-30 2021-02-05 三优生物医药(上海)有限公司 针对冠状病毒的具有中和活性的抗体及其用途
CN119367545B (zh) * 2025-01-02 2025-04-08 山东第一医科大学(山东省医学科学院) 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525383A (ja) 2015-08-07 2018-09-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗−ａｎｇｐｔｌ８抗体及びその使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040100A1 (en) 1998-02-09 1999-08-12 Human Genome Sciences, Inc. 45 human secreted proteins
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US6956108B2 (en) 1997-06-16 2005-10-18 Genentech, Inc. PRO1184 antibodies
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
KR100510795B1 (en) 1999-08-31 2005-08-30 Compositions and Methods for the Treatment of Tumor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
KR20100017169A (ko) 2007-05-22 2010-02-16 노파르티스 아게 Ｆｇｆ２１-관련 장애의 치료, 진단 및 검출 방법
JP2013512672A (ja) 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
EP3822287A1 (en) 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
PL3439689T3 (pl) 2016-04-08 2022-01-31 Regeneron Pharmaceuticals, Inc. Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525383A (ja) 2015-08-07 2018-09-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗−ａｎｇｐｔｌ８抗体及びその使用
JP2021090449A (ja) 2015-08-07 2021-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗−ａｎｇｐｔｌ８抗体及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, 2013, vol. 110, no. 40, pp. 1610916114

Also Published As

Publication number Publication date
US20180134781A1 (en) 2018-05-17
EP3541839A1 (en) 2019-09-25
CA3044249A1 (en) 2018-05-24
JP2020500852A (ja) 2020-01-16
CN110036029A (zh) 2019-07-19
KR20190078650A (ko) 2019-07-04
MA46842A (fr) 2019-09-25
MX2019005651A (es) 2019-11-12
ZA201902608B (en) 2020-07-29
IL266564A (en) 2019-07-31
MX382035B (es) 2025-03-13
EA201991203A1 (ru) 2019-10-31
US10442856B2 (en) 2019-10-15
WO2018094112A1 (en) 2018-05-24
AU2017363143A1 (en) 2019-05-23
AU2017363143B2 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
JP7141333B2 (ja) 抗－ａｎｇｐｔｌ８抗体及びその使用
JP7436603B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
US10442856B2 (en) Methods of treating obesity with anti-ANGPTL8 antibodies
US9657099B2 (en) Anti-glucagon antibodies
AU2011331998B2 (en) Human antibodies to the glucagon receptor
JP7042816B2 (ja) レプチン受容体をアンタゴナイズする抗原結合性タンパク質
CN104540852A (zh) 具有pH-依赖性结合特性的抗-PCSK9抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220829

R150 Certificate of patent or registration of utility model

Ref document number: 7133551

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250